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ORIGINAL ARTICLE
Cirrhotic cardiomyopathy: is there any correlation between the stage of
cardiac impairment and the severity of liver disease?
Rania Hammamia, Mouna Boudabbousb, Jihen Jdidic, Fatma Trabelsib, Fakher Mrouaa, Rahma Kallela,
Ali Amourib, Dorra Abida, Nabil Tahrib, Leila Abida and Samir Kammouna
aCardiology Department, HediChaker Hospital, Sfax, Tunisia; bHepatoGastrology Department, HediChaker Hospital, Sfax, Tunisia;
cEpidemiology Department, HediChaker Hospital, Sfax, Tunisia
ABSTRACT
Cirrhotic cardiomyopathy is associated with poor prognosis and risk of acute heart failure
after liver transplantation or interventional procedures. We aimed to assess the relation-
ship between the severity of cardiac impairment and hepatic disease. Eighty patients and
eighty controls underwent echocardiography, tissue Doppler imaging and speckle tracking
measures. We assess the correlation between echocardiographic parameters and Child
and MELD scores. Systolic parameters function (s wave, p < 0.001) and global longitudinal
strain (p < 0.001) as well as diastolic parameters were significantly more impaired in
cirrhotic patients compared to controls. There were no differences among the different
groups in ‘Child score’ regarding systolic function as well as diastolic function.
Paradoxically, the left atrium size correlated positively to both Child (p = 0.01, r = 0.26)
and MELD scores (p = 0.02, r = 0.24). Left ventricular ejection fraction was significantly
lower in decompensated patients as compared to compensated patients(p = 0.02).. We
did not identify any association between severity of liver disease and cardiac dysfunction.
Therefore, a transthoracic echocardiography should be performed in all cirrhotic patients
before interventional and surgical procedures regardless of the severity of liver disease.
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1. Introduction
In 1953, cirrhotic cardiomyopathy (CC) was described
for the first time in patients with alcoholic cirrhosis, in
the absence of concomitant cardiac disease, as a
hyperdynamic circulation with high cardiac output
and peripheric vessel vasodilatation.[1] This entity has
poor prognosis, especially in patients undergoing inva-
sive procedures such as transjugular intrahepatic por-
tosystemic shunt insertion (TIPS), hepatic surgery, and
hepatic transplantation.[2,3] Recently, diastolic dys-
function (DD) has been shown to be a predictor of
mortality in cirrhotic patients.[4] Although some
authors suggest an increasing prevalence of DD in
the advanced stages of liver disease (decompensated
cirrhosis with large ascites), a clear correlation between
the severity of liver cirrhosis and the stages of cardiac
dysfunction has not yet been established. Identifying
this correlation is difficult given the perpetual changes
in the definition of CC. In 2005, the World Congress of
Gastroenterology in Montreal Working Group defined
CC as ‘a chronic cardiac dysfunction in patients with
cirrhosis, characterized by blunted contractile respon-
siveness to stress, and/or altered diastolic relaxation
with electrophysiological abnormalities, in the absence
of known cardiac disease’.[5,6,7] Then, several studies,
using new tools to assess CC, reported widely different
prevalence rates.
The hypotheses of circulatory dysfunction in cirrho-
sis are evolving substantially. Initially, it was explained
by a generalized peripheral arterial vasodilation with
low peripheral vascular resistance. Subsequent studies
on cirrhotic patients with ascites indicated that arter-
ial vasodilation occurs predominantly in the splanch-
nic circulation with compensatory vasoconstriction in
extra splanchnic organs, including brain, kidneys and
liver.[6,7] Therefore, the hemodynamic hypothesis is
not the only proposed mechanism of systolic dysfunc-
tion. The physiopathology is more complex and many
mechanisms are involved, such as impairment of beta
adrenergic receptors, alteration of the ion channels
function in myocardial cells, and the toxic effect of
NO overproduction.[8–10] The correlation of these
mechanisms with the severity of liver damage is diffi-
cult to assess.
We aimed in this study to check in a selected
group of cirrhotic patients whether there is a relation-
ship between the stage of liver impairment assessed
by conventional scores (CHILD and MELD) and the
severity of cardiac impairment assessed by the new
ultrasound tools and according to the guidelines of
the American Society of Echocardiography.[11,12]
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2. Patients and methods
This was a cross-sectional study. We included all the
patients who came to the department of gastroenter-
ology between January 2013 and December 2015.
Cirrhosis was diagnosed according to clinical,
laboratory, ultrasonographic and histological findings.
We excluded all the conditions that could potentially
affect cardiac function: diabetes, hypertension, taba-
gism, pulmonary diseases, suspected coronary disease,
age > 75 years or < 20 years, hepatocellular carcinoma,
renal disease, anemia (hemoglobin<10 g dl–1), thyroid
disease, alcoholic cirrhosis, and abnormal electrocardio-
gram (repolarization disorders and rhythm anomalies).
We also excluded patients with bad echogenicity.
A12-lead surface EGG was obtained from all subjects
in the supine position immediately before echocardio-
graphy. All measurements were made by one observer
who was blinded to the patients’ characteristics.
All patients were examined at rest in the left
lateral decubitus position using a Vivid-9 ultrasound
system (GE Healthcare, Chicago, IL, USA). The echo-
cardiographic measurements and analyses were per-
formed by the same physician blinded to the
findings of the other physician. Left ventricle (LV)
diameters, LV mass and grading of LV hypertrophy,
left ventricle ejection fraction (LVEF) (Simpson
method), left atrium area and LV diastolic function
were assessed as recently recommended by the
American and European societies of echocardiogra-
phy.[11,12] The analyses by two-dimensional
speckle-tracking echocardiography were performed
offline using EchoPac version 110.1.0 workstation,
Chicago,IL,USA with blinding to the clinical charac-
teristics of the patients. The measurements of LV
longitudinal systolic strain was performed at basal,
mid, and apical levels in the apical four-chamber,
two-chamber, and long-axis views.
The LV mass was calculated according to the ASE
convention: LVM (g) = 0.8 (1.04 (DIVGd + SIVd + PPd)3
– DIVGd3) + 0.6 g, and then indexed to the body area.
[6] In that regard, severe LV hypertrophy was defined
as LV mass ≥ 122 g m–2 in women and ≥ 149 g m–2
in men.
LV diastolic function was assessed in terms of LV
inflow diastolic velocities (in the E/A ratio, E is the
velocity of the mitral flow at the beginning of diastole
and A the velocity of the mitral flow during the late
phase of diastole, just after atrial contraction), and
lateral mitral annulus motion (s wave). Early (Ea)
peak diastolic velocities of the LV inflow were deter-
mined by pulsed wave Doppler with the sample
volume placed at the tips of the mitral valve.
In all patients, the diastolic function pattern was
classified by using LV inflow and mitral annulus dia-
stolic velocities as well as left atrial size according to
the current recommendations.[13,14]
Normal diastolic function was defined as mitral E/A
ratio < 0.8, E/Ea < 10, peak tricuspid regurgitation
velocity < 2.8 and normal left atrium size.
Grade I diastolic dysfunction was defined as mitral
E/A ratio < 0.8, E/Ea < 10, peak tricuspid regurgitation
velocity < 2.8 m s–1 and increased left atrium size.
Grade II diastolic dysfunction was defined as mitral
E/A between 0.8 and 2, E/Ea between 10 and 14, peak
tricuspid regurgitation velocity > 2.8 m s–1 and
increased left atrium size.
Grade III diastolic dysfunction was defined asmitral
E/A between 0.8 and 2, E/Ea > 14, peak tricuspid
regurgitation velocity > 2.8 m s–1 and increased left
atrium size.
The assessment of liver disease severity was based
on calculating Child and MELD scores.
The MELD score was calculated according to the
formula MELD = 9.57 (log creatinine) + 3.78 (log
bilirubine) + 11.2 (log INR) + 6.43.
2.1. Statistical analysis
All calculations were performed with the PASW statis-
tical package (SPSS version 20.0, Chicago, IL, USA).
Chi-square and Fisher exact tests were used to com-
pare dichotomous variables where appropriate.
Mann–Whitney and Wilcoxon tests were used to com-
pare nonparametric continuous variables. P-values <
0.05 were considered significant. Spearman rank cor-
relation was used to assess the association between
echocardiographic parameters and MELD and Child
scores. The results are expressed as the mean ± stan-
dard deviation and 95% confidence interval when
indicated.
3. Results
Between January 2013 and December 2015, 274
patients with liver cirrhosis presented consecutively
to the department of hepatogastroenterology of our
hospital. Based on the selection criteria, only 80
patients were included in our study. The etiology of
the cirrhosis was post-viral in most cases (Table 1).
Many patients (77.5%) were under beta blockers when
undergoing the echocardiography. Systolic para-
meters function (s wave, p < 0.001) and global long-
itudinal strain (p < 0.001)) as well as diastolic
parameters were significantly more impaired in cirrho-
tic patients compared to controls (Table 2).
3.1. Systolic function
According to the above-mentioned definition (LVEF <
55%), systolic dysfunction was found in 14 patients
(17.5%). Using the new echocardiographic techniques,
s wave on the lateral LV wall < 8 cm s–1 was found in 33
patients (41.3%) and global longitudinal strain (GLS) >
2 R. HAMMAMI ET AL.
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−18% was found in 18 patients (22.5%). The basal strain
was significantly lower than the apical strain (−18 ± 3 vs.
−22 ± 5, p < 0.001). In fact, when considering only the
basal strain, we found that 40% of the patients had a low
basal strain > −18%. But there was no difference among
the different stages of Child scores in the prevalence of
systolic parameters impairment (Table 2). Moreover,
there was no correlation between Child score or MELD
score and LVEF, s wave, global longitudinal strain or the
Tei index (Table 3).
Paradoxically, the ejection fraction was significantly
lower in patients with decompensated cirrhosis com-
pared with compensated patients (Table 4), and
among decompensated patients there was a negative
correlation between the Child score and cardiac
output.
3.2. Diastolic function
Diastolic dysfunction was found in 61.2% of our
patients, and it was mild (stage I or II) in most cases.
No diastolic function parameter was correlated to the
severity of cirrhosis (Table 3). Besides, there was no
difference in the severity of diastolic function among
the different groups of Child A, B and C (Table 2).
3.3. Morphological changes
The left atrium was more enlarged in the advanced
stage of liver disease; there was a positive correlation
between the size of the left atrium and Child and
MELD scores (Table 4). The LV mass was larger in
patients with ascites than in compensated patients,
but there was no statistical correlation between LV
mass and Child or MELD score.
3.4. Electrophysiological abnormalities
We found a longer QTc interval in patients with a
more compromised liver function (patients with
Child C) (Table 2), and we concluded that there was
a positive correlation between the QTc interval and
the severity of cirrhosis as assessed by Child score
(p < 0.001, r = 0.46) (Figure 1).
4. Discussion
The prevalence of cirrhotic cardiomyopathy varies
widely among studies because of the lack of a clear
definition, the variability of the tools used to assess this
entity, and the variability of inclusion criteria.
According to the World Congress of Gastroenterology,
the diagnostic criteria of CC are a systolic function (a
resting ejection fraction < 55% or a blunted increase in
cardiac output after exercise or pharmacological stress),
or a diastolic function (E/A mitral age corrected < 1, or
Table 1. Clinical data of cirrhotic patients.
Characteristics Data
Age (years) 55 ± 14
Gender male/female, n (%) 42 (52.5%)/38 (47.5%)
Etiology Viral (hepatitis B.C): 42 (52.6%)
Cryptogenic: 21 (26.1%)
Other causes: 17(21.25%)
Compensated/decompensated 41 (51.25%)/39 (48.75%)
Child-Plugh
A, n (%) 24 (30%)
B, n (%) 36 (45%)
C, n (%) 20 (25%)
Mean value of MELD score 14.2 ± 4.98
Propranolol intake, n (%) 62 (77.5%)
Table 2. Comparison of echocardiographic data between patients and controls and among the three groups of Child score.
All patients
N = 80
Controls
N = 80 P*
Child A
(n = 24)
Child B
(n = 36)
Child C
(n = 20) P**
Age 55 ± 14 51 ± 12 0.08 55 ± 15 53 ± 14 59 ± 12 0.42
Heart rhythm 75.8 ± 19 74.5 ± 11 0.74 78.4 ± 23 76.3 ± 18 71.8 ± 18 0.54
Beta blockers intake n
(%)
62(77.5%) _ _ 16(6.7%) 28(77.8%) 18(90%) 0.182
QTc (ms) 420.65 ± 31.25 349 ± 45 <0.001 408.41 ± 24 419.69 ± 36 420 ± 31 0.001
Prolonged QTc 23(28.8%) 1(1.3%) <0.001 2(8.3%) 10(27.8%) 11(55%) 0.003
LVEF 60.48 ± 7.7 62.2 ± 7.01 0.08 62.2 ± 6.04 60.7 ± 6.6 60.4 ± 7.7 0.32
LV s wave 9 ± 1.9 11.5 ± 2.7 <0.001 9.1 ± 2.2 9.06 ± 1.7 8.7 ± 1.7 0.76
LV Tei 0.44 ± 0.16 0.44 ± 0.11 0.78 0.48 ± 0.15 0.43 ± 0.17 0.39 ± 0.16 0.25
Global longitudinal strain −19.8 ± 2.8 −22.01 ± 2.6 <0.001 −19.6 ± 3.2 −19.96 ± 2.9 −19.86 ± 2.86 0.44
Apical strain −22.19 ± 5.1 −22.4 ± 4.1 0.71 −22.03 ± 4.5 −22.24 ± 5.1 −22.29 ± 6.01 0.99
Median strain −20.76 ± 3.7 −20.4 ± 2.5 0.52 −20.583.7 −21.3 ± 3.7 −21.3 ± 3.7 0.73
Basal strain −16.6 ± 6 −23.12 ± 8.9 <0.001 −18.34 ± 3.6 −16.5 ± 12.1 −18.37 ± 8.49 0.95
LA area 22.09 ± 4.9 15.6 ± 3.1 <0.001 19.98 ± 5.6 23.04 ± 4.8 22.9 ± 4.9 0.02
LV mass 200.6 ± 59 179 ± 55 0.02 188 ± 45 205 ± 27 207 ± 14 0.47
E wave 82 ± 21 73 ± 15 0.004 80.6 ± 16 85 ± 24 80 ± 23 0.65
A wave 72 ± 20 59 ± 11 <0.001 72.5 ± 15 72.8 ± 24 70.6 ± 13 0.92
Deceleration time 210 ± 49 181 ± 41 0.001 205 ± 47 199 ± 57 224 ± 57 0.27
Mitral E/A ratio 1.28 ± 0.6 1.26 ± 0.32 0.83 1.22 ± 0.55 1.3 ± 0.86 1.17 ± 0.47 0.89
Mitral E/Ea ratio 7.34 ± 3.07 4.9 ± 1.48 <0.001 6.92 ± 2.32 7.85 ± 3.7 6.9 ± 2.38 0.85
Mitral profile
Normal 39(48.8%) 72(90%) <0.001 14 (58.3%) 14(38.9%) 11(55%) 0.45
Stage I 19(23.8%) 6(7.5%) 5(20.8%) 9(25%) 5(25%)
Stage II 11(13.8%) 0(0%) 2(8.3%) 6(16.7%) 3(15%)
Stage III 11(13.8%) 2(2.5%) 3(12.5%) 7(19.4%) 1(5%)
P*: comparison between patients and controls; P**: comparison between the three groups of Child score.
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deceleration time > 200 ms, or isovolumetric relaxation
(IVRT) > 80 ms). Other supportive criteria were added,
such as prolongation of QT interval, abnormal chrono-
tropic response, enlarged left atrium, increased myo-
cardial mass, increased brain natriuretic peptide, and
increased troponin I.[3] Using this definition, the pre-
valence of CC in the literature has been estimated
between 50 and 70% in several studies.[15–17]
New ultrasound techniques can detect the early signs
of cardiac damage, especially impairment of longitudinal
function (the s wave on DTI and the global longitudinal
strain on the speckle tracking analysis). According to the
recent guidelines of the American Society of
Echocardiography and different studies using the Vivid
system, longitudinal systolic dysfunction is suspected if
the global longitudinal strain (GLS) is superior to −18%
and if the s wave is inferior to 8 cm s–1.[11,18] In our
study, 17.5% of the patients had a LVEF < 55%, while
22.5% had a GLS > −18% and 41.3% had an s wave <
8 cm s–1. In fact, when considering only the basal long-
itudinal strain, we found that 40% of the patients had a
low basal longitudinal strain > −18%, which is concor-
dant with the degree of s wave impairment; both para-
meters assess basal segments. Moreover, the basal strain
was significantly lower than the apical strain. Therefore,
we conclude that in cirrhotic cardiomyopathy, systolic
dysfunction concerns first the basal myocardium, and
that is why we found a higher prevalence of CC when
based on the s wave or the basal longitudinal strain.
However, there was no correlation between the stage
of cirrhosis and any of the systolic function parameters
(LVEF, s wave, Tei index, GLS, basal strain). Disruptions in
systolic function are harder to detect, as they are subtle
in the resting state and may be detectable only when
they are aggravated by physiological stress. Our findings
are in agreement with previous studies, as no trial has
found a correlation between systolic function and the
severity of cirrhosis (Table 5). In our patient population,
we found a negative correlation between the cardiac
output and the severity of cirrhosis in patients with
ascites, and the LVEF was also significantly higher in
compensated patients than in decompensated patients.
Recent studies indicate that although cardiac output is
significantly elevated in patients with cirrhosis, it
decreases during the course of the disease and it is
generally low in patients with hepatorenal syndrome.
[19,20] Nazar et al. showed that cardiac output was
significantly lower in patients with ascites and in those
with a marked increase in plasma renin compared to
those with normal or moderately increased renin. One
of the proposedmechanisms is the lack of cardiac chron-
otropic response to the activation of sympathetic ner-
vous activity.[14] We did not observe significant
differences in heart rate between patients with compen-
sated cirrhosis and those with ascites or among the
different stages of Child. This is in agreement with the
findings of Nazar et al., as they did not find an increase in
the heart rate of decompensated patients despite arterial
hypotension and intense activation of sympathetic ner-
vous activity.[14] A lack of increment in heart rate is also
observed in cirrhosis during severe sepsis and following
paracentesis-induced circulatory dysfunction.
Li et al. [20] observed that in cirrhotic patients,
increases in MELD score were accompanied by an
increase in LV end systolic diameter, LV end diastolic
diameter and interventricular septum thickness, with
no significant changes in LV posterior wall thickness
Table 4. Comparison of echocardiographic data between
compensated and decompensated patients.
Compensated
patients
(n = 41)
Decompensated
patients
(n = 39) p
Heart rhythm 78.38 ± 21 73.16 ± 17 0.24
QTc (ms) 411 ± 34 430.4 ± 24 0.005
Prolonged QTc 8 (19.5%) 15(38.5%) 0.06
LVEF 62.42 ± 6.03 58.43 ± 8.9 0.02
LVSF 43.6 ± 10 45.1 ± 11 0.55
LV s wave 9.05 ± 2.14 8.95 ± 1.64 0.8
LV Tei 0.45 ± 0.17 0.42 ± 0.15 0.35
Global longitudinal
strain
−19.78 ± 3 −19.95 ± 2.73 0.78
Apical strain −22.19 ± 4.8 −22.1 ± 5.57 0.99
Median strain −20.9 ± 3.5 −20.57 ± 3.9 0.16
Basal strain −18.8 −16.17 0.65
Cardiac output 4.1 ± 1.4 3.9 ± 1.4 0.48
LA area 20.71 ± 5.06 23.54 ± 4.41 0.01
SPAP 36.9 ± 8 34.6 ± 9 0.25
Mitral E/A ratio 1.25 ± 0.56 1.32 ± 0.78 0.66
Mitral E/Ea ratio 7.63 ± 3.3 7.04 ± 2.7 0.38
Mitral profile 0.93
Normal 17(41.5%) 14(35.9%)
Stage I 13(31.7%) 15(38.5%)
Stage II 3(7.3%) 3(7.7%)
Stage III 8(19.5%) 7(17.9%)
LV mass 115 ± 26 135 ± 43 0.02
LV hypertrophy 18(39.1%) 21(61.8%) 0.04
Cirrhotic
cardiomyopathy
27(65.9%) 29(74.4%) 0.4
Table 3. Correlation of ultrasound parameters with liver dis-
ease scores.
Correlation of left ventricular systolic function parameters with liver
disease scores
Child score MELD score
Parameter p r p r
LVEF 0.11 −0.17 0.79 −0.04
LVSF 0.34 −0.1 0.8 −0.14
LV s wave 0.69 0.04 0.3 0.16
LV Tei index 0.22 −0.13 0.8 0.04
Cardiac output 0.25 −0.12 0.43 0.12
Longitudinal global strain 0.95 0.007 0.55 −0.06
Apical strain 0.68 −0.046 0.68 −0.046
Median strain 0.89 −0.15 0.15 −0.16
Basal strain 0.2 −0.144 0.2 −0.144
LV mass 0.39 0.09 0.65 0.05
Correlation of left ventricular diastolic function parameters with liver
disease score
Child score MELD score
Parameter p r p r
E wave 0.97 −0.003 0.39 0.09
A wave 0.36 −0.1 0.36 −0.1
E/A ratio 0.74 0.03 0.96 0.005
E/Ea ratio 0.85 −0.021 0.12 0.17
LA area 0.01 0.26 0.02 0.24
4 R. HAMMAMI ET AL.
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and LVEF regardless of MELD score classification; cor-
relation analysis showed that the LV end diastolic
diameter was positively correlated with MELD score.
In our patient population, the size of the left atrium
was positively correlated to the severity of the liver
disease. In the publication of Sylvestre et al. [17], left-
atrial diameter, left-ventricular diastolic diameter and
systolic pulmonary artery pressure were significantly
Figure 1. Correlation between Child score and QTc (ms).
Table 5. Correlation between liver disease severity and cardiac impairment in the literature.
Reference
Number
(N) Age/sex Aim Morphological changes Systolic function Diastolic function
[17] 184 54 ± 11
122M/62F
Compare patients
with MELD
score < 16 and
those with
MELD score ≥
16
Correlation between Meld score
and left atrial diameter, left
ventricular diastolic diameter
and pulmonary arterial
pressure
No significant
differences
between both
groups as regards
to systolic function
parameters
No significant differences of
diastolic function
parameters between
both groups
[18] 74 58 ± 10
44M/30F
Compare patients
with Child A, B,
C
Compare patients
with MELD < 15
and MELD ≥ 15
No differences between the
different Child or MELD
groups as regards to ventricle
and left atrium measurements
as well as the IVS
No statistic
differences
between patients
with CHILD A, B,C
in regards to
systolic function.
No statistic differences
between patients with
CHILD A, B,C in regards to
diastolic function
[21] 49 52 ± 15.2
63M/37F
Compare patients
with Child A, B
and C
_ _ The relation between
severity of cirrhosis and
diastolic dysfunction was
significant (p = 0.048)
Patients with Child C had
more frequently a
diastolic dysfunction
compared with the other
groups
[22] 40 _ Compare
compensated
and
decompensated
patients
No significant differences
between both groups in left
atrium and left ventricle
measurements
No significant
differences
between both
groups as regards
to systolic function
parameters
E/A ratio was decreased
(p < 0.05) in patients
with ascites (0.9±0.2)
versus those without
ascites (1.3 +/- 0.4).
The PAPS was slightly
elevated in patients with
ascites (35 ± 5 mm Hg)
versus those with no
ascites (28 ± 5), p < 0.05
[23] 92 53.2 ± 11.3
years
62 males
Compare diastolic
dysfunction
among the
different stages
of Child
No differences between the
three groups, in regards to
LVESD, LVEDD and LAD
No difference among
groups in regards
to LVEF and LVSF
Diastolic dysfunction stage
II was more prevalent
among patients with
Child C compared with
patients with Child A or B
[19] 52 7.66 ± 4.16 years
27 M/ 25 F
Compare
compensated
and
decompensated
patients
RV was larger in compensated
group (p = 0.05)
IVS was thinner in
compensated patients
(p = 0.04)
No difference
between both
groups
No differences between
both groups
LVESD, left ventricle end systolic diameter; LVEDD, left ventricle end diastolic diameter; LAD, left atrial diameter; LVEF, left ventricular ejection fraction;
LVSF, left ventricular shortening fraction; IVS, interventricular septum; RV, right ventricle
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correlated with the MELD score. However, diastolic
function did not correlate with the severity of liver
disease. Conversely, many studies did not find any
differences in left atrium and left ventricle size
among the different Child or MELD groups.
[14,18,21,24,25,26] The physiopathology of morpholo-
gical changes is not well understood. In cardiovascu-
lar diseases, as well as diabetes and arterial
hypertension, the mechanism of these changes is
the severity of diastolic dysfunction, but there was
no correlation between the severity of the liver dis-
ease and the stage of diastolic dysfunction in our
patients. The hepatopulmonary syndrome, defined as
an oxygenation arterial defect secondary to intra-pul-
monary vascular dilatation, seems to be the main
cause of left atrium enlargement in liver disease.
Moreover, the selection of patients is very important.
Unlike previous studies, in our study we excluded all
the conditions that could change the size of the left
atrium, such as diabetes and hypertension. This
strengthens and gives more value to our findings.
The use of complex algorithms results in some
variability in the classification of DD among echocar-
diographers and leads to variability of the reported
prevalence of DD among more recent studies on
cirrhosis. Initially, the definition of DD in cirrhotic
people was based on the E/A ratio, but this parameter
is strongly dependent on preload and often requires
age correction. Unlike transmitral valve Doppler flow,
TDI directly measures the velocity of myocardial dis-
placement during the expansion of the left ventricle
in the diastole and is therefore independent of
volume status and left atrial pressure. Most of the
papers have included TDI parameters in the definition
of DD. The prevalence of DD in our study was 61.2%,
but in most cases it was mild and not related to the
etiology of cirrhosis. A recent study based on TDI
parameters found a DD prevalence of about 46% in
cirrhotic patients and concluded that DD was a sensi-
tive marker of advanced cirrhosis type 1 hepatorenal
syndrome development, and a predictor of mortal-
ity.[27]
Some authors found a lower mean E/A ratio in the
ascitic subgroup as compared to non-ascitic sub-
group.[21,28] Pozzi et al. [28] showed that removal
of ascitic fluid by total paracentesis reduced the A
wave velocity and increased the E/A ratio to values
similar to those of cirrhotic patients without ascites,
but they remained abnormal compared to healthy
controls. The mechanism of DD in cirrhotic patients
is multifactorial. Some authors suggest that diastolic
dysfunction is secondary to the increased preload
status, while others consider that it is related to the
increased ventricular stiffness seen in DD, including a
combination of myocardial hypertrophy, fibrosis, and
subendothelial edema; 75% of patients with LVDD
and cirrhosis have cardiac hypertrophy.[4,5,29]
However, overt structural changes in the left ventricle
are not a prerequisite for diastolic dysfunction.
Indeed, a normal left ventricular morphology in
patients with cirrhosis does not exclude cardiac dys-
function. Interestingly, alternative pathogenic
mechanisms such as a decrease in cardiomyocyte
metabolism have been recently proposed to explain
DD and its reversibility after liver transplantation.
Alterations in membrane physical properties play an
important role in the impaired β-adrenoceptor and
ion channel function in the hearts of cirrhotic rats.
[30] Moreover, the intake of β-blockers could have
aggravated the diastolic dysfunction. Nazar et al. [14]
compared three groups of cirrhotic patients: those
with compensated cirrhosis and, therefore, without
effective arterial hypovolemia, those with ascites with-
out hepatorenal syndrome (HRS) (this group repre-
sents patients with moderately decreased arterial
blood volume), and those with ascites and HRS.
There was a progressive decrease in mean arterial
pressure and a progressive increase in plasma renin
activity and plasma norepinephrine from the first
group to the third group, reflecting a progressive
deterioration in circulatory function from compen-
sated cirrhosis to development of HRS. But there
were no differences between the three groups in
relation to the presence of DD or LV ejection fraction.
In addition, there were no differences if we consider
each individual parameter used to assess diastolic
dysfunction.
Finally, repolarization abnormalities represent sup-
portive diagnostic criteria of cirrhotic cardiomyopathy.
QT prolongation is frequent in patients with cirrhosis,
and in previous studies it correlated well with the
severity of the liver disease. Accordingly, at least 60%
of patients with end-stage liver disease have this elec-
trocardiographic abnormality. In a prospective study,
Zambruni et al. [31] found a longer QTc interval in
patients with a more compromised liver function.
Patients with a QTc interval > 440 ms were 27% of
those with Child A vs. 56% of those with Child B/C
(p = 0.02), 36% of patients with MELD < 15 vs. 63% of
MELD > 15 (p = 0.03), and 35% in patients without
ascites vs. 62% in patients with ascites (p = 0.03).[31]
Conversely, the prevalence of sudden cardiac death
and torsades des pointes is reported to be low in
cirrhotic people.[31] In our study, the QT interval cor-
related well to Child and MELD scores and was signifi-
cantly more prolonged in patients with ascites as
compared to those without ascites. But we did not
find any correlation between the QT interval and the
other parameters of diastolic or systolic function.
Prolongation of the QT interval appeared to be a
result of a combination of ion-channel dysfunction,
plasma membrane abnormalities and receptor path-
way defects and may also worsen after interventional
procedures and hepatic transplantation. However, the
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administration of β-blockers is effective for reducing
the QT interval only in patients with a prolonged
baseline value.[32]
4.1. Limitations of the study
The limitation of our study is the unavailability of
brain natriuretic peptide analysis, which is recognized
as important in the evaluation of DD.[21] Moreover,
we did not perform a stress test (physical activity or
pharmacological stress), which could have better
revealed a subclinical cardiac dysfunction.
5. Conclusion
The mechanism of cardiac involvement in patients
with cirrhosis seems to be complex and multifactorial,
and there is no correlation between the severity of
cirrhosis and the stage of cardiomyopathy. Therefore,
in order to prepare the best post-procedural manage-
ment of cirrhotic patients, echocardiography is
required for all patients before any interventional
procedure or liver transplantation regardless of the
stage of cirrhosis.
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